Tel Aviv, Israel, March 3, 2022 – Tarsier Pharma, an advanced clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for blinding ocular diseases, has announced that its CEO and Chairperson, Dr. Daphne Haim-Langford, will participate today as keynote speaker at the Israeli Society for Vision and Eye Research (ISVER) Annual Meeting.
Founded in Israel in 1979, ISVER has established a unique platform for the presentation of original scientific research projects performed in Israel by vision scientists, Ophthalmologists and Optometrists. ISVER is dedicated for the promotion of eye and vision research in Israel. It is connected as a chapter affiliate with ARVO – the Association for Research of Vision and Ophthalmology.
“It is a great honor for me to deliver a keynote speech at ISVER, which gathers Ophthalmology professionals and enthusiasts, such as myself, to celebrate and exchange cutting-edge ocular research”, said Dr. Daphne Haim-Langford. “I am privileged to be part of the thriving Israeli innovation ecosystem in Ophthalmology, where our efforts at Tarsier Pharma to disrupt the treatment paradigm of ocular inflammatory diseases, constitute one part of the puzzle, out of various breakthrough ocular innovations”, she added.
About Tarsier Pharma
Tarsier Pharma is a phase-3 pharmaceutical company, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular blinding diseases. TRS is a bio-inspired breakthrough proprietary technology platform, based on a new chemical entity with novel mechanism of action, that demonstrated safety and efficacy in a rare debilitating and blinding indication.
Lead product candidate for uveitic glaucoma
Non-infectious uveitis is an autoimmune blinding ocular inflammation, considered the third leading cause of blindness in the developed world. Tarsier’s TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – that is considered an end-stage condition of uveitis. Once a uveitis patient has also developed glaucoma (uveitic glaucoma), the only available treatments for active inflammation, which are steroids, should be avoided due to their side effects of expediting glaucoma and vision loss. Thus, TRS01 has the potential to become the standard of care for uveitic glaucoma. Currently Tarsier is running TRS4VISION phase-3 clinical trial in subjects with non-infectious anterior uveitis including uveitic glaucoma.